Trials / Active Not Recruiting
Active Not RecruitingNCT05380492
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Perceive Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
Detailed description
This is a prospective, multi-center safety phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of three dose levels of VOY-101 therapy in subjects with late-stage non-neovascular age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VOY-101 | Intravitreal injection of VOY-101 |
Timeline
- Start date
- 2022-11-17
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2022-05-19
- Last updated
- 2024-04-11
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05380492. Inclusion in this directory is not an endorsement.